In the current IP landscape it is wise to be prepared for attacks on important patents, as Lars Kellberg, corporate vice president and corporate patents of Novo Nordisk, explains to LSIPR.
Pharmaceutical company UCB injects a significant amount of revenue into R&D, but it is mindful of the risks attached to drug investment. Global head of IP Stéphane Drouin explains more in an interview with LSIPR.
Resolving complex legal disputes and explaining technical concepts in a courtroom are all part of the job for Regeneron’s Larry Coury, who talks to LSIPR about life as senior director of dispute resolution.
Richard Henderson, an award-winning scientist based in Cambridge, UK, is seeking to make his next important discovery in the field of biological electron microscopy, as LSIPR finds out.
A prolific patentee, Audrey Goddard believes women should be patenting more inventions in the STEM industries. She explains more to LSIPR.
Anthony Atala combines the roles of surgeon and researcher in regenerative medicine, allowing him to stay mindful of why his work is important. He talks to LSIPR about his twin professions.
Finding therapies that are safe, effective and available requires hard work and putting patients first, according to Daniela Verthelyi of the FDA, who discusses her role as chief of the immunology laboratory at the government agency.
From the Unified Patent Court to life sciences industrial strategy, there are many issues for Sean Dennehey to contend with as deputy CEO of the UK Intellectual Property Office. He talks to LSIPR about how he managed.
As CEO of the UK BioIndustry Association, Steve Bates works closely with industry and government and, by 2025, he wants the UK to become home to the third biggest global biotech cluster, as he explains to LSIPR.
Jennifer Doudna was selected in the LSIPR 50 2017 publication for her influence on the life sciences industry. She featured in the business and innovation section, as LSIPR reports.